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Over the past 30 years, steep increases in tobacco taxes, advertising bans, and bans on 
smoking in public places have reduced the daily smoking rate among Australian adults to 
16%.1, 2 Australia was an early adopter of graphic health warnings on cigarette packs and 
mandatory plain packaging of cigarettes.2 In 2011 Australia joined Brazil, Canada, and a 
number of other European countries in banning the sale of e-cigarettes or electronic nicotine 
delivery systems (ENDS).3  
Unlike in other substance use fields, harm reduction (THR) strategies have never played a 
role in Australian tobacco policy. These strategies aim to reduce tobacco-related harm by 
encouraging smokers to use less harmful ways of obtaining nicotine, such as using smokeless 
tobacco or electronic nicotine delivery systems (ENDS). Australia’s national tobacco strategy 
makes no mention of THR as a strategy and there are major legal and regulatory obstacles to 
THR,4 including a ban on the sale of smokeless tobacco since 1991.5  
The Australian laws covering ENDS are complex and vary between the states but they 
effectively ban their sale. Since 2011, personal importation of ENDS as an unapproved 
cessation aid has only been allowed on medical prescription. State drugs and poisons 
legislation prevent the retail sale, possession and/or use of nicotine for recreational purposes 
without a licence, approval or permit.6  
Some states have also banned the sale of vaporising devices that do not contain nicotine. 
They have extended laws, originally designed to prevent the sale of cigarette-like 
confectionary and toys to children, to prohibit the sale of any products that ‘resemble’ 
tobacco products.6 The national tobacco control strategy indicates that consideration is being 
given to “whether there is a need to increase restrictions on their availability and use”.4  
Despite these bans, the number of Australian smokers who have ever tried ENDS increased 
from 2.0% in 2010 to 16.8% in 2013.6 Similar increases have been reported in other 
surveys.1, 7 These rates of use are lower than those in the UK (where ENDS can still be 
legally sold as general consumer products) where ever use among smokers increased from 
9.6% in 2010 to 38.8%% in 2013.7, 8 
The Cancer Council, National Heart Foundation6 and many leading tobacco control advocates 
in Australia support the ban on the sale of ENDS9-12 (see table 1 for a summary of their 
reasons). They argue that it: prevents the tobacco industry (which now owns some ENDS 
products10) from undermining smoke free policies by promoting dual use (i.e. encouraging 
smokers to keep smoking and only use ENDS when smoking is prohibited); prevents the 
widespread use of ENDS from renormalising smoking by increasing the visibility of a 
behaviour that resembles smoking; and prevents ENDS being used to promote cigarette 
smoking among adolescents and young adults.  
There has been very little criticism of the ban within the Australian public health community. 
Nonetheless, the ban can be criticised on ethical and other grounds (see table 1). It is 
paternalistic because it denies adult smokers the right to use a less harmful form of nicotine in 
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order to prevent cigarette uptake among youth. It is also an incoherent form of risk regulation 
in banning a less harmful product (ENDS) while allowing the most harmful, tobacco 
cigarettes, to be freely sold. It disadvantages smokers who are heavily addicted and want to 
reduce the risks of their smoking. It has produced a black market in nicotine sold over the 
internet and ‘under the counter’. And it precludes any regulation of ENDS and nicotine refills 
to reduce risks to consumers and others. 
A policy compromise?  
The public health harms feared by those who support a ban on ENDS are most likely to occur 
if the sale and promotion of these products is unregulated. This has arguably been the case by 
default in parts of Europe, the UK, and the USA for the past several years while different 
models of regulation have been debated.3  
We do not have to choose between banning ENDS sales and allowing their unregulated sale. 
We can regulate sales in ways that address the legitimate concerns of those who support a 
ban, while still allowing smokers to buy ENDS.13 For example, adult smokers could be 
allowed to buy approved ENDS products from a restricted number of licensed sales outlets. 
These sales could be regulated in ways that facilitate research to inform future decisions 
about how to regulate ENDS.  
Advertising of ENDS products could be banned and consumer law could be used to ensure 
their safety to users and others (e.g. to children by requiring child-resistant containers for 
nicotine). At the point of sale, purchasers could be: advised to avoid dual use (except as a 
time-limited path to quitting); and clearly told that we do not have definitive evidence on the 
health effects of using ENDS as a long term alternative to cigarette smoking.  
This type of regulation would facilitate research on the uptake and use of ENDS. Regulations 
could, for example, make reporting sales data and user characteristics (age, sex, smoker 
status) a condition of being licensed to sell ENDS. Researchers could be funded and 
facilitated to conduct long-term follow up studies of ENDS purchasers in order to discover: 
who uses ENDS and for how long; how many users cease smoking, engage in dual use and 
cease all nicotine use; and what the health effects in the medium term are of using ENDS, 
either alone, or in combination with tobacco smoking (dual use).  
This policy respects smoker autonomy and eliminates the injustice of preventing smokers 
from accessing ENDS while allowing free access to cigarettes. It would also provide better 
consumer protection of ENDS users, regulate promotion of these products and reduce the size 
of the black market for ENDS products.  
It could also be readily reversed if ENDS prove as disappointing as their critics predict. If, 
however, ENDS assist quitting and are much safer substitutes for combustible cigarettes, as 
their advocates claim, then these restrictions could be relaxed. This could be done while also 
increasing restrictions on the sale of cigarettes, e.g. by reducing the number of outlets in 
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which cigarettes can be sold; allowing ENDS to be sold in the same places so that they can 
compete with combustible cigarettes among current smokers; and reducing young people’s 
access to both products to minimise the recruitment of new smokers and vapers among 
adolescents and young adults. 
References 
1. Adkison SE, O’Connor RJ, Bansal-Travers M, et al. Electronic nicotine delivery 
systems: international tobacco control four-country survey. Am J Prev Med 2013; 
44:207-15. 
2. Scollo M, Winstanley M. Tobacco in Australia: Facts & issues, 4th edn. Melbourne: 
Cancer Council Victoria, 2012. 
3. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation 2014; 
129:1972-86. 
4. Intergovernmental Committee on Drugs. National Tobacco Strategy 2012-2108. 
Canberra: Commonwealth of Australia, 2012. 
http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/Content/
national_ts_2012_2018_html#31pf (accessed July 7, 2014). 
5. Gartner CE, Hall WD. Should Australia lift its ban on low nitrosamine smokeless 
tobacco products? Med J Aust 2008; 188:44-46. 
6. Cancer Council Australia, Heart Foundation. Position statement - Electronic 
cigarettes. Revision as of May 14, 2014. 
http://wiki.cancer.org.au/prevention_mw/index.php?oldid=5242 (accessed May 29, 
2014). 
7. Yong H, Borland R, Balmford J, McNeill A, Hitchman S, Cummings KM. Changes in 
e-cigarette awareness, trial, use and relative harm beliefs among current and former 
smokers in four high-income countries.  Poster presented at the Society for Research 
on Nicotine and Tobacco (SRNT) Annual Meeting; Boston, USA, 2013. 
8. West R, Beard E, Brown J. Trends in use of electronic cigarettes in England 2011-
2013 (slides). Smoking Toolkit Study 2013. http://www.rjwest.co.uk/slides.php 
(accessed July 7, 2014). 
9. Chapman S. Simon Chapman on e-cigarettes: the best and the worst case scenarios for 
public health. BMJ Blogs 2014; March 14. 
http://blogs.bmj.com/bmj/2014/03/14/simon-chapman-on-e-cigarettes-the-best-and-
the-worst-case-scenarios-for-public-health/ (accessed June 4, 2014). 
10. Chapman S. Simon Chapman: Why is Big Tobacco investing in e-cigarettes? BMJ 
Blogs 2014; March 20. http://blogs.bmj.com/bmj/2014/03/20/simon-chapman-why-is-
big-tobacco-investing-in-e-cigarettes/ (accessed June 4, 2014). 
11. Daube M. Bring on the end of tobacco use – but not a total ban tomorrow The 
Conversation 2012; August 23. http://theconversation.com/bring-on-the-end-of-
tobacco-use-but-not-a-total-ban-tomorrow-8881 (accessed June 4, 2014). 
12. Freeman B. E-cigarettes and the marketing push that surprised everyone. BMJ Blogs 
2013; October 2. http://blogs.bmj.com/tc/2013/10/02/e-cigarettes-and-the-marketing-
push-that-surprised-everyone (accessed June 4, 2014). 
5 
 
13. Gartner CE, Hall WD, Borland R. How should we regulate smokeless tobacco 
products and e-cigarettes? Med J Aust 2012; 197:611-2. 
 
  
6 
 
Table legends 
Table 1: competing perspectives on a ban on ENDS and allowing limited sales by opponents 
and proponents of ENDS 
Table 2: competing predictions about the effects of allowing ENDS by proponents and 
opponents of a ban  
  
7 
 
Policy on ENDS A ban on ENDS Allowing restricted sales 
View of those who 
oppose sales  
Avoids: 
• Dual use 
• Renormalising 
smoking 
• New young recruits to 
ENDS and smoking 
• Adverse health effects 
of long term ENDS use 
Will:  
• Deter quitting smoking 
• Encourage dual use 
• Renormalise smoking 
• Recruit new smokers 
• Recruit new young non-
smoking ENDS users 
View of those who 
would allow sales  
 
• Paternalistic policy  
• Unfair to smokers 
• Incoherent risk 
management 
• Creates black market 
• No consumer 
regulation 
• Will reduce cigarette 
smoking  
• Respects smoker 
autonomy 
• Fairer to smokers 
• More coherent risk 
management 
• Minimise black market 
• Provide consumer 
protection 
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Outcome ENDS Proponents ENDS Opponents 
% smokers quitting 
with ENDS 
Much higher than NRT No better than NRT 
% smokers 
switching to ENDS 
Most or at least a sizeable 
minority 
Negligible 
% smokers who 
engage in dual use 
A minority The majority  
% nonsmokers  
who become 
smokers via ENDS  
Negligible Substantial 
Adverse health 
effects of long term 
vaping vs smoking 
Negligible Substantial 
Net effect on 
tobacco-related 
harm 
A substantial reduction  A substantial increase  
